Economic consequences to society of pandemic H1N1 influenza 2009 - preliminary results for Sweden.
Experiments using a microsimulation platform show that vaccination against pandemic H1N1 influenza is highly cost-effective. Swedish society may reduce the costs of pandemic by about SEK 2.5 billion (approximately EUR 250 million) if at least 60 per cent of the population is vaccinated, even if costs related to death cases are excluded. The cost reduction primarily results from reduced absenteeism. These results are preliminary and based on comprehensive assumptions about the infectiousness and morbidity of the pandemic, which are uncertain in the current situation.
Brouwers
L
L
Swedish Institute for Infectious Disease Control (Smittskyddsinstitutet, SMI), Solna, Sweden. lisa.brouwers@smi.se
Cakici
B
B
Camitz
M
M
Tegnell
A
A
Boman
M
M
D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks / Q000191:economics* / Q000517:prevention & control* / Q000706:statistics & numerical data; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D015994:Incidence; D007252:Influenza Vaccines / Q000191:economics* / Q000627:therapeutic use*; D007251:Influenza, Human / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D032541:Mass Vaccination / Q000191:economics / Q000706:statistics & numerical data; D010865:Pilot Projects; D011159:Population Surveillance; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D013548:Sweden / Q000453:epidemiology; D016896:Treatment Outcome
D007252:Influenza Vaccines